Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.53 |
| ▸ | ARG2 | P78540 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.46 |
| ▸ | NOS2 | P35228 | 3/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.38 |
| ▸ | GGT1 | P19440 | 4/20 | 0.38 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | BHMT | Q93088 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27630394 | 1.00 | ARG1 (0.53) | ARG1ARG2GRIK1GRIK2NOS2 | |
| SCHEMBL119988 | 1.00 | ARG1 (0.53) | ARG1ARG2GRIK1GRIK2NOS2 | |
| SCHEMBL16230008 | 1.00 | ARG1 (0.53) | ARG1ARG2GRIK1GRIK2NOS2 | |
| SCHEMBL31482265 | 0.98 | ARG1 (0.52) | ARG1ARG2GRIK1GRIK2NOS2 | |
| Hydrochloric Acid SCHEMBL11572696 | 0.98 | ARG2 (0.52) | ARG1ARG2GRIK1GRIK2NOS2 | |
| SCHEMBL28083645 | 0.98 | ARG1 (0.52) | ARG1ARG2GRIK1GRIK2NOS2 | |
| Glutamine SCHEMBL28579184 | 0.87 | ALOX15 (0.59) | ARG1ARG2GRIK1GRIK2NOS2 | |
| SCHEMBL4543471 | 0.83 | ALDH1A1 (0.46) | ARG1ARG2GRIK1GRIK2NOS2 | |
| SCHEMBL11131002 | 0.83 | ALOX5 (0.40) | ARG1ARG2GRIK1GRIK2NOS2 | |
| SCHEMBL1158206 | 0.83 | ALDH1A1 (0.46) | ARG1ARG2GRIK1GRIK2NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1722 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122081201-A | ANCA-related vasculitis glomerular endothelial cell injury model, construction method and application thereof, and application of BACH1 inhibitor | — | 2026-05-26 | — | — | CN | claimed |
| CN-122005906-A | Hydrogel dressing for promoting healing of diabetic wound surface as well as preparation method and application thereof | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | 2026-05-12 | — | — | CN | claimed |
| EP-4724065-A1 | SYNERGISTIC COMPOSITION FOR MODULATING EXPRESSION OF CD38 | Celagenex Research (India) Pvt. Ltd. (IN) | 2026-04-15 | — | — | EP | claimed |
| EP-4709166-A1 | NOVEL INSECTICIDAL MIXTURES FOR CONTROLLING AND PROTECTING CROPS | ADAMA MAKHTESHIM LTD. (IL) | 2026-03-18 | — | — | EP | claimed |
| EP-4706675-A1 | CYSTEINE-ENGINEERED CHIMERIC ANTIGEN RECEPTOR | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-11 | — | — | EP | claimed |
| EP-4706676-A1 | CYSTEINE-ENGINEERED ANTIGEN-BINDING DOMAINS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-03-11 | — | — | EP | claimed |
| US-12378584-B2 | Methionine analogue synthesis | ENGENES BIOTECH GMBH (AT) | 2025-08-05 | — | — | US | claimed |
| CN-120192253-A | Separation method of S-allyl-L-cysteine and/or S-propenyl-L-cysteine in leek seeds | 中国矿业大学 | 2025-06-24 | — | — | CN | claimed |
| US-20250171739-A1 | PROCESS FOR GENERATING THERAPEUTIC COMPOSITIONS OF ENGINEERED CELLS | JUNO THERAPEUTICS, INC. (US) | 2025-05-29 | — | — | US | claimed |
| US-12258580-B2 | Process for generating therapeutic compositions of engineered cells | JUNO THERAPEUTICS, INC. (US) | 2025-03-25 | — | — | US | claimed |
| US-20020119104-A1 | For therapy of oral mucositis, esophagitis, cystitis, sinusitis, asthma, colitis, GERD, proctitis, stomatitis, celiac disease, inflammatory bowel disease, and Crohn's disease | ENDO PHARMACEUTICALS INC. | 2002-08-29 | — | — | US | claimed |
| US-20020103137-A1 | Method of treating environmental stress | SHISEIDO CO., LTD. | 2002-08-01 | — | — | US | claimed |
| WO-2002041837-A2 | TREATMENT OF MUCOSITIS | RXKINETIX, INC. (US) | 2002-05-30 | — | — | WO | claimed |
| WO-2001078783-A2 | COMPOSITIONS COMPRISING NATURAL AGENTS FOR TREATMENT OF CANCER | HAUSER, INC. (US) | 2001-10-25 | — | — | WO | claimed |
| US-6271396-B1 | Use of organosulfur compounds for effecting a bathocromic shift in the UV/vis absorption bands of carotenoids | BASF AKTIENGESELLSCHAFT (DE) | 2001-08-07 | — | — | US | claimed |
| US-6254871-B1 | Therapeutic uses of specially processed garlic for sickle cell disease | WAKUNAGA OF AMERICA CO., LTD. | 2001-07-03 | — | — | US | claimed |
| WO-2001035972-A1 | THERAPEUTIC USES OF SPECIALLY PROCESSED GARLIC FOR SICKLE CELL DISEASE | WAKUNAGA OF AMERICA CO., LTD. (US) | 2001-05-25 | — | — | WO | claimed |
| US-5206270-A | Administering S-allylcysteine | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1993-04-27 | — | — | US | claimed |
| EP-0429080-B1 | METHOD FOR PREPARING AN S-ALLYLCYSTEINE-CONTAINING COMPOSITION | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1993-04-21 | — | — | EP | claimed |
| US-5093122-A | METHOD FOR PREPARING AN S-ALLYLCYSTEINE-CONTAINING COMPOSITION | WAKUNAGA SEIYAKU KABUSHIKI KAISHA (JP) | 1992-03-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119104-A1 | For therapy of oral mucositis, esophagitis, cystitis, sinusitis, asthma, colitis, GERD, proctitis, stomatitis, celiac disease, inflammatory bowel disease, and Crohn's disease | CFTR, HRH2, SI | ARG1 1129/4885ARG2 1278/4885GRIK1 1774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.